Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
The cell and gene therapy (CAGT) pipeline represents incredible promise for the patients who need these products, many of whom have rare conditions without approved treatments or others who have exhausted treatment options. In bringing these novel therapies to market, sponsors face new regulatory and manufacturing challenges, operational complexity, and obstacles to market access.
Parexel helps sponsors innovate in this growing but uncertain space, so our experienced colleagues have strategized approaches to the persistent and prevalent barriers that CAGT developers may encounter. In this guide, we share some of those strategies — actionable insights for protecting the potential of your product in every phase of development.
Related Insights
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Three ways to improve your chances that insurers will pay for a new CGT
Feb 18, 2021
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Chris Learn joins Parexel as Head of the Cell and Gene Center of Excellence
Apr 4, 2022
Video
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Blog
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021